FDA approves Rimadyl in new injectable form

Pfizer Animal Health announces the U.S. Food and Drug Administration (FDA) approved Rimadyl Injectable as a pain reliever for dogs. The injectable form, when combined with oral take-home dosing, creates the first complete non-steroidal anti-inflammatory drug to manage canine pain caused by osteoarthritis as well as soft tissue and orthopedic surgery, the company says. Its the only COX-2 selective pain reliever approved by the FDA for 24-hour control of canine osteoarthritis and postoperative pain with one dose, the company adds. The approval means veterinarians and dog owners will have increased confidence they can manage canine pain more effectively than ever before, says Dr. Michael McFarland, director of the Pfizer Animal Health Sedation and Pain Management Team. Dog owners are very concerned about the comfort of their animals, especially when they suffer from arthritis or require a surgical procedure, McFarland says. With the approval of Rimadyl Injectable, veterinarians and pet owners can work together to manage pain and set the animal on an effective path to recovery.Rimadyl, on the market since 1997, is the leading veterinary pain reliever in the United States, the company says. Since its initial approval, the drug has provided effective pain relief for more than 10 million dogs, the company adds.

For fastest response call (800) 720-3647 or visit the Web site at www.rimadyl.com.